Join
Live feed
·
PRReleasevia Quantisnow
KemPharm Inc. logo

KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

ByQuantisnow·Wall Street's wire, on your screen.
KMPH· KemPharm Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KMPH (KemPharm Inc.) and more on Quantisnow.